Colon cancer awareness: Why early detection saves lives
March marks Colon Cancer Awareness Month, a time to act against one of the most common yet preventable cancers. The Gastroenterology team at HealthBay is urging individuals to prioritise screenings, as early detection can dramatically increase survival rates. Colon cancer, also known as bowel or colorectal cancer, develops silently, often showing no symptoms in its early stages. However, when diagnosed early, the survival rate soars to 90 per cent. Unfortunately, many people delay screenings due to a lack of symptoms or awareness, increasing the risk of late-stage detection when treatment options become limited.
Why awareness matters
Colon cancer typically starts as small, benign polyps in the colon or rectum, which can become cancerous over time. The real danger lies in its silent progression, with no clear warning signs in the early stages. This is why routine screenings are essential, even in the absence of symptoms.
The risk of colon cancer rises with age, prompting experts to recommend screenings from age 45 for those without symptoms. However, individuals with a family history of colon cancer, inflammatory bowel disease, or a history of polyps should begin screening even earlier. Lifestyle choices also play a role - diets high in processed foods and smoking have been linked to an increased risk.
Effective screening methods
Two key screening methods - colonoscopy and faecal occult blood tests (FOBT) - offer highly effective ways to detect colon cancer early. Yet, many avoid these tests due to fear or misconceptions, potentially delaying life-saving diagnoses.
Bridging the gap with free screenings
HealthBay, a leading healthcare provider in Dubai, is making screening more accessible. Throughout Colon Cancer Awareness Month, HealthBay is offering free FOBT screenings for individuals aged 45 and above, helping to detect early warning signs before symptoms appear.
For those requiring further assessment, HealthBay provides comprehensive colonoscopy packages at its state-of-the-art Gastroenterology & Digestive Care Centre in Al Wasl. The centre is equipped with an advanced endoscopy suite and Western-trained specialists, ensuring world-class care for gastrointestinal health.
How to protect yourself
Preventing colon cancer starts with proactive health choices:
Schedule a Screening - If you're 45 or older, speak to your doctor about a colonoscopy or an FOBT test. If you have a family history of colon cancer, early screening is even more critical.
Adopt a Healthy Lifestyle - A diet rich in fibre, lean proteins, and vegetables, combined with regular exercise and eliminating smoking, can reduce your risk.
Watch for Symptoms - Although colon cancer can develop silently, signs like unexplained weight loss, persistent bowel changes, or rectal bleeding should never be ignored. Seek medical advice immediately if you experience these symptoms.
A collective effort for prevention
Preventing colon cancer requires awareness, responsibility, and proactive health choices. Education, open conversations, and regular check-ups play a key role in early detection.
HealthBay is committed to making screenings more accessible and encouraging early detection. But the first step begins with you. This Colon Cancer Awareness Month, take charge of your health because early detection is the most powerful tool against colon cancer. Book your screening today.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Arabian Post
27-06-2025
- Arabian Post
Tanoto Foundation Backs Landmark Research to Unlock the Code of Asian Prevalent Diseases
Understanding Asian Cancers and Diabetes Through an Asian Lens SINGAPORE – Media OutReach Newswire – 27 June 2025 – Tanoto Foundation today announced the funding of two transformative, Singapore-based medical research projects focused on diseases that disproportionately affect Asian populations: prevalent and aggressive cancers, and young-onset Type 2 diabetes. The multi-year initiatives aim to generate data-driven insights that can accelerate diagnosis, improve patient outcomes, and guide public health policy. NCCS and SGH secure research funding from Tanoto Foundation for projects tackling Asian-prevalent cancers and young-onset diabetes to drive breakthroughs in regional health Despite global strides in medicine, Asia continues to face rising rates of cancer and diabetes – diseases that are biologically and clinically distinct in Asian populations but remain under-researched due to a lack of region-specific data. The two research projects, from National Cancer Centre Singapore and Singapore General Hospital, will focus on filling these gaps through deep genomic studies and innovative risk-prediction models. ADVERTISEMENT Imelda Tanoto, Member of the Board of Trustees, Tanoto Foundation said: 'Singapore is well-positioned to lead in medical science. It has strong research institutions and a population that reflects the diversity of Asia. By supporting researchers here who are focused on health issues that affect Asians, we hope to help drive discoveries that make a real difference to people's lives — both in Singapore and across the region.' Tackling Asian-Prevalent Cancers Led by Dr Jason Chan, Medical Oncologist, National Cancer Centre Singapore, the research will investigate four types of cancers with high prevalence and poor outcomes in Asia: Breast Cancer in Asian Women, marked by earlier onset and biological differences compared to Western populations T/NK-Cell Lymphomas, an aggressive blood cancer dominant in East Asians with limited treatment options Bile Duct Cancer (Cholangiocarcinoma), increasingly linked to environmental exposures specific to Asia Rare Asian Cancers, collectively neglected but accounting for up to 25% of all cases in the region These cancers are devastating but remain poorly understood because most research has focused on Western populations,' said Dr Chan. 'By decoding their molecular and genomic landscapes in Asian patients, we want to uncover new diagnostic and therapeutic opportunities to benefit patients.' A key feature of the project is its open-access commitment: anonymised data will be freely available to the broader research community to accelerate further discovery and collaboration. Unmasking Diabetes Risk in Young Singaporeans The second research project, led by Dr Daphne Gardner, Endocrinologist, Singapore General Hospital, will address the rising incidence of Type 2 diabetes in young adults, particularly prevalent in Singapore, where 1 in 5 young adults have prediabetes or diabetes, despite being of normal weight. ADVERTISEMENT Unlike traditional assessments that rely heavily on BMI and family history, this project will develop a next-generation risk prediction tool by incorporating non-traditional indicators such as body fat distribution, continuous glucose monitoring, and health-seeking behaviour. 'Many young Asians with diabetes don't fit the usual risk profile. They're lean, active, and often overlooked by current screening models,' said Dr Gardner. 'We want to change that by identifying new risk signals and developing tools that are tailored to Singapore's population and beyond.' Findings from the study aim to inform national diabetes screening guidelines and lead to earlier interventions that can curb long-term complications. Singapore as a Hub for Medical Research Advancement In addition to previously supported research projects, these two initiatives reflect a growing recognition of Singapore's role in advancing precision medicine for Asian populations, driven by strong clinical infrastructure, genomic capabilities, and public-private partnerships. Imelda Tanoto added: 'We believe precision health can change how we treat and prevent diseases. We're supporting researchers who are not only breaking new ground, but also making sure their work reaches people and communities across Asia. This is something deeply personal to us — it's about improving lives in a way that's inclusive, meaningful, and lasting.' This announcement marks a key milestone in Tanoto Foundation's continuing effort to improve the quality of healthcare and health standards, leading to longer and better healthspans. Hashtag: #TanotoFoundation The issuer is solely responsible for the content of this announcement. About Tanoto Foundation At Tanoto Foundation, we unlock human potential, help communities thrive, and create lasting impact. Founded in 1981 by Sukanto Tanoto and Tinah Bingei Tanoto, we are an independent family foundation that believes in providing every person with the opportunity to realize his or her full potential. To do so, we catalyse systems change in education and healthcare. Our approach is impact-first, collaborative, and evidence-based. We invest for the long term and strive to develop leaders who can drive sustained, positive outcomes. More information is available at
Gulf Today
11-06-2025
- Gulf Today
UAE performs first robotic surgery with HIPEC
Cleveland Clinic Abu Dhabi has successfully performed the UAE's first robotic cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) to treat a rare appendiceal tumour, in a medical milestone that reinforces Abu Dhabi's position as a global destination for innovative healthcare. The complex procedure, performed on a 48-year-old patient, involved the removal of multiple internal organs to prevent the spread of the tumour in her abdomen. This groundbreaking procedure was led by Dr Yasir Akmal, Staff Physician in the Digestive Disease Institute at Cleveland Clinic Abu Dhabi and an American Fellowship-trained surgical oncologist, and a multi-disciplinary team. Appendiceal tumours account for less than 1 per cent of malignancies worldwide and are found in approximately 1.4 per cent of patients who undergo an appendectomy. The patient initially presented symptoms resembling appendicitis, leading to the removal of her appendix. However, during the procedure, her surgeon discovered gelatinous deposits, a jelly-like substance, in the abdominal cavity. A subsequent pathology report confirmed the presence of a rare low-grade mucinous neoplasm, a tumour that, if untreated, could spread throughout the abdomen and result in a condition known as pseudomyxoma peritonei or 'jelly belly.' Dr Georges-Pascal Haber, Chief Executive Officer of Cleveland Clinic Abu Dhabi, said, 'We are pushing the boundaries of robotic surgery and are proud to have used such an advanced technology for a complex procedure like Paola's. Cleveland Clinic Abu Dhabi is a leader in surgical innovation, continuously refining minimally invasive techniques to improve outcomes and enhance quality of life.' Following the tumour removal, HIPEC treatment (Hyperthermic Intraperitoneal Chemotherapy) was administered- a technique where heated chemotherapy (42 degrees Celsius) is circulated within the abdominal cavity for 90 minutes to eliminate any residual cancer cells. Highlighting both the preventive and curative nature of the surgery, Dr Akmal said that the patient's condition was diagnosed at an advanced but treatable stage, and thanks to the timely intervention of the multidisciplinary team, supported by specialised AI-driven diagnostic tools, the team was able to navigate the process of eliminating the cancer cells in her body with precision. WAM
Al Etihad
09-06-2025
- Al Etihad
Cleveland Clinic Abu Dhabi performs UAE's first robotic cytoreductive surgery with HIPEC
9 June 2025 13:04 ABU DHABI (WAM) Cleveland Clinic Abu Dhabi (CCAD) has successfully performed the UAE's first robotic cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) to treat a rare appendiceal tumour, in a medical milestone that reinforces Abu Dhabi's position as a global destination for innovative complex procedure, performed on a 48-year-old patient, involved the removal of multiple internal organs to prevent the spread of the tumour in her groundbreaking procedure was led by Dr. Yasir Akmal, a Staff Physician in the Digestive Disease Institute at Cleveland Clinic Abu Dhabi an American Fellowship-trained surgical oncologist, and a multi-disciplinary tumours account for less than 1 per cent of malignancies worldwide and are found in approximately 1.4 per cent of patients who undergo an patient initially presented symptoms resembling appendicitis, leading to the removal of her appendix. However, during the procedure, her surgeon discovered gelatinous deposits, a jelly-like substance, in the abdominal cavity. A subsequent pathology report confirmed the presence of a rare low-grade mucinous neoplasm, a tumour that, if untreated, could spread throughout the abdomen and result in a condition known as pseudomyxoma peritonei or 'jelly belly."Dr. Georges-Pascal Haber, Chief Executive Officer of Cleveland Clinic Abu Dhabi, said, 'We are pushing the boundaries of robotic surgery and are proud to have used such an advanced technology for a complex procedure like Paola's. Cleveland Clinic Abu Dhabi is a leader in surgical innovation, continuously refining minimally invasive techniques to improve outcomes and enhance quality of life.'Following the tumour removal, HIPEC treatment (Hyperthermic Intraperitoneal Chemotherapy) was administered— a technique where heated chemotherapy (42 degrees Celsius) is circulated within the abdominal cavity for 90 minutes to eliminate any residual cancer cells. Highlighting both the preventive and curative nature of the surgery, Dr. Akmal said that the patient's condition was diagnosed at an advanced but treatable stage, and thanks to the timely intervention of the multidisciplinary team, supported by specialised AI-driven diagnostic tools, the team was able to navigate the process of eliminating the cancer cells in her body with precision.
